Associated Papers
Acute myeloid leukemia with bipotential erythroid and megakaryocytic differentiation: a case series and literature review.
Liu LW et al.
Journal of Hematopathology, 2025
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
McCarter JGW et al.
Blood Advances, 2023
37142255 (PubMed )
Supplement: BLOODA_ADV-2023-009675-mmc1.xlsx › supplemental_Table_2-Mutations
Clinical features and prognosis of pediatric acute lymphocytic leukemia with JAK-STAT pathway genetic abnormalities: a case series.
Hu M et al.
Annals of Hematology, 2023
Base editing screens map mutations affecting interferon-γ signaling in cancer.
Coelho MA et al.
Cancer Cell, 2023
36669486 (PubMed )
Supplement: mmc4.xlsx › BE_variants_-clinical_relevance
Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?
Klein K et al.
Cancers, 2021
Chromosome 21 gain is dispensable for transient myeloproliferative disorder driven by a novel GATA1 mutation.
Lukes J et al.
Leukemia, 2020
Genetic Characterization of Molecular Targets in Korean Patients with Gastrointestinal Stromal Tumors.
Park J et al.
Journal of Gastric Cancer, 2020
JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation.
Xiao W et al.
Leukemia, 2018
JAK1 somatic mutation in a myeloproliferative neoplasm.
Arulogun SO et al.
Haematologica, 2017
Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.
Hornakova T et al.
Haematologica, 2011
Select a paper to view details